Back to Journals » Vascular Health and Risk Management » Volume 3 » Issue 1

Moexipril and left ventricular hypertrophy

Authors George S Chrysant, PK Nguyen

Published 15 March 2007 Volume 2007:3(1) Pages 23—30


George S Chrysant1, PK Nguyen

University of Oklahoma, 1Director, Advanced Cardiac Imaging, INTEGRIS Heart Hospital, Oklahoma City, OK, USA

Abstract: Angiotensin-converting enzyme (ACE) inhibitors today are the standard therapy of patients with myocardial infarction and heart failure due to their proven beneficial effects in left ventricular remodeling and left ventricular function. ACE inhibitors have also been demonstrated to lead to regression of left ventricular hypertrophy (LVH). It is believed that the mechanism of action of LVH regression with ACE inhibitors arises from more than simple blood pressure reduction. LVH is an important risk factor for cardiovascular disease morbidity and mortality independent of blood pressure. Moexipril hydrochloride is a long-acting, non-sulfhydryl ACE inhibitor that can be taken once daily for the treatment of hypertension. Moexipril has now also been demonstrated to have beneficial effects on LVH and can lead to LVH regression.

Keywords: moexipril, ACE inhibitor, cardiovascular disease, left ventricular hypertropy

Download Article [PDF]